NO20022591L - Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre - Google Patents

Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre

Info

Publication number
NO20022591L
NO20022591L NO20022591A NO20022591A NO20022591L NO 20022591 L NO20022591 L NO 20022591L NO 20022591 A NO20022591 A NO 20022591A NO 20022591 A NO20022591 A NO 20022591A NO 20022591 L NO20022591 L NO 20022591L
Authority
NO
Norway
Prior art keywords
ethoxy
compound
pharmaceutically acceptable
particle size
acceptable salt
Prior art date
Application number
NO20022591A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022591D0 (no
Inventor
Agneta Hallgren
Kristina Roos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022591D0 publication Critical patent/NO20022591D0/no
Publication of NO20022591L publication Critical patent/NO20022591L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022591A 1999-12-03 2002-05-31 Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre NO20022591L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (2)

Publication Number Publication Date
NO20022591D0 NO20022591D0 (no) 2002-05-31
NO20022591L true NO20022591L (no) 2002-05-31

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022591A NO20022591L (no) 1999-12-03 2002-05-31 Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre

Country Status (32)

Country Link
EP (1) EP1237854B1 (de)
JP (1) JP2003515580A (de)
KR (1) KR20020067538A (de)
CN (1) CN1216859C (de)
AR (1) AR029456A1 (de)
AT (1) ATE251131T1 (de)
AU (1) AU766036B2 (de)
BR (1) BR0016135A (de)
CA (1) CA2392029A1 (de)
CO (1) CO5271736A1 (de)
CZ (1) CZ20021839A3 (de)
DE (1) DE60005710T2 (de)
DK (1) DK1237854T3 (de)
EE (1) EE200200284A (de)
ES (1) ES2208444T3 (de)
HK (1) HK1049324B (de)
HU (1) HUP0203692A3 (de)
IL (1) IL149516A0 (de)
IS (1) IS6399A (de)
MX (1) MXPA02005165A (de)
MY (1) MY125099A (de)
NO (1) NO20022591L (de)
NZ (1) NZ518926A (de)
PL (1) PL355372A1 (de)
PT (1) PT1237854E (de)
RU (1) RU2248966C2 (de)
SE (1) SE9904413D0 (de)
SK (1) SK7662002A3 (de)
TR (1) TR200400003T4 (de)
UA (1) UA73959C2 (de)
WO (1) WO2001040169A1 (de)
ZA (1) ZA200203797B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9812770A (pt) 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
UA60386C2 (uk) 1998-10-29 2003-10-15 Reddys Laboratories Ltd Спосіб одержання похідних 3-[4-[2-(феноксазин-10-іл)метокси]феніл]пропіонової кислоти (варіанти) та проміжні сполуки для їх отримання
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1689383B1 (de) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
EP1586573B1 (de) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
UA100497C2 (ru) 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
ES2445049T3 (es) 2007-03-08 2014-02-27 Albireo Ab Derivados del ácido 3-fenilpropiónico y su uso en el tratamiento de la enfermedad inflamatoria intestinal
KR101560844B1 (ko) 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
EP1237854A1 (de) 2002-09-11
IS6399A (is) 2002-05-28
NO20022591D0 (no) 2002-05-31
CO5271736A1 (es) 2003-04-30
RU2002113169A (ru) 2004-01-20
HUP0203692A2 (hu) 2003-03-28
DE60005710D1 (en) 2003-11-06
IL149516A0 (en) 2002-11-10
CN1216859C (zh) 2005-08-31
JP2003515580A (ja) 2003-05-07
WO2001040169A1 (en) 2001-06-07
EE200200284A (et) 2003-08-15
PL355372A1 (en) 2004-04-19
KR20020067538A (ko) 2002-08-22
NZ518926A (en) 2003-11-28
BR0016135A (pt) 2002-08-20
SE9904413D0 (sv) 1999-12-03
PT1237854E (pt) 2004-02-27
HK1049324B (en) 2004-04-30
CZ20021839A3 (cs) 2002-08-14
ATE251131T1 (de) 2003-10-15
TR200400003T4 (tr) 2004-02-23
EP1237854B1 (de) 2003-10-01
HK1049324A1 (en) 2003-05-09
SK7662002A3 (en) 2002-10-08
DK1237854T3 (da) 2004-01-12
CN1402704A (zh) 2003-03-12
AR029456A1 (es) 2003-07-02
ES2208444T3 (es) 2004-06-16
AU766036B2 (en) 2003-10-09
RU2248966C2 (ru) 2005-03-27
UA73959C2 (en) 2005-10-17
HUP0203692A3 (en) 2005-05-30
MXPA02005165A (es) 2003-09-25
AU2034801A (en) 2001-06-12
ZA200203797B (en) 2003-08-13
DE60005710T2 (de) 2004-08-05
MY125099A (en) 2006-07-31
CA2392029A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
SE9904413D0 (sv) Comminuted form
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
NO20055892L (no) Karboksylsyrederivater
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
UA92472C2 (ru) Фармацевтическая композиция, которая содержит 4-{4-[3-(4-хлор-3-трифторметилфенил)-уреидо]- 3-фторфенокси}-пиридин-2-карбоновой кислоты метиламид (варианты), способ получения твердой дисперсии указанного соединения и способ лечения с применением указанного соединения (варианты)
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
NO20064830L (no) Sammensetning for fast farmasoytisk preparat av solifenacin eller salter derav
BR0010683A (pt) Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
JP5674676B2 (ja) 結腸癌発生を予防または低減する方法
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
MEP35208A (bs) Pripremanje sterilnih vodenih suspenzija koje sadrže mikronizovane kristalne aktivne sastojke za inhalaciju
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
SE9904421D0 (sv) New compounds
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
BRPI0506704A (pt) composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético
NO20054897L (no) Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav
HUP9902559A2 (hu) Paracetamolt és drotavenint tartalmazó gyógyszerkészítmény és eljárás előállítására